Optimizing the dose and schedule of KW-2449, FLT3/Aurora inhibitor, through analysis of in vivo target inhibition

7069 Background: FLT3 inhibitors have shown promising activity in AML patients with FLT3 activating mutations. FLT3 mutant AML cells are killed when FLT3 is inhibited in sustained fashion to less t...